In Manhattan one night this week, a group of doctors and scientists listened intently as a tall, dark-haired surgeon talked about the biggest subject in medicine: cancer. Dr. Saul P. Lehv of Harlem Hospital was reporting on the first controlled study of a new cancer treatment. In guarded, technical language, he described a series of cases.
Patient E.G., 65, was dying of prostate cancer. The disease had spread to his bones and spine. He was paralyzed from the waist down. His legs were doubled up in a spasm and he was faint with pain. Two months ago the doctor began to give...
To continue reading:
or
Log-In
